~" A survey of all patients (173 males and 294 females) registered with primary intraspinal neoplasms in the Norwegian Cancer Registry from 1955 through 1986 is presented. Annual age-adjusted incidence rates of new tumors per one million population were three for males and five for females. Altogether, 89% of the tumors were verified histologically. Meningioma was the most common tumor type, followed by ependymoma and neurilemoma. Intraspinal ependymomas accounted for 34.5 % of all 223 ependymomas of the central nervous system, whereas only 0.2% of the 3046 glioblastomas were found intraspinally. Patients with intraspinal meningioma had a better life expectancy than those with intracranial meningioma. The 5-year relative survival rate for patients with intraspinal ependymoma was 88.9% in contrast to 24.4% for patients with intracranial ependymoma.
S
TATISTICAL data on primary intraspinal neoplasms are generally meager and biased I since most series are from referral centers that receive selected cases and not from defined populations. The few populationbased studies that have been published give annual incidence rates of new tumors per 100,000 population of 0.9 (90 patients), 5 1.1 (18 patients), 2 and 1.4 (26 patients). 1o
The aim of the present work was to determine the incidence of primary intraspinal neoplasms in a defined population. The Cancer Registry data from the total Norwegian population over a period of 32 years was therefore analyzed in order to establish valid data on incidence rates, tumor types, and relative survival times. The relationship between the occurrence of intraspinal and intracranial neoplasms was also investigated.
Clinical Material and Methods

Source of Patients
Norwegian hospital clinicians, general practitioners, and pathologists report all cancer cases as well as benign tumors of the central nervous system (CNS) to the Cancer Registry. All primary neoplasms are registered as separate entities. Data on the patient (such as identification number, municipality, and date of registration), on the neoplasm (such as site, histological type), and on the hospital (such as clinical department and pathology file numbers) are registered in each case, together with the clinicopathological basis for the diagnosis (for example, histological examination, medical imaging, or death certificate). Norwegians numbered 3.4 million in 1955 and 4.2 million in 1986; each individual has a unique personal identification code, thus ensuring complete follow-up data and hindering faulty registration of tumors. The personal identification code also makes it possible to match the cancer data with the death registry of the Central Bureau of Statistics; thus, the Cancer Registry receives information on both date and cause of death. A description of the registration routines, the population, and the validity of the data has been published elsewhere. 3
Incidence Rates
All patients with a primary intraspinal neoplasm who were registered during the period 1955 to 1986 were included. Primary intraspinal neoplasms were defined as all benign and malignant primary tumors arising within the spinal cord and cauda equina, from the intradural portion of nerves, and in the meninges. The incidence rates were age-adjusted by a direct method based on a standard European population. 
Primary intraspinal neoplasms in Norway
Survival and Prognosis
Relative survival rates were determined in comparison with the age-matched population v for patients up to 60 years of age at the time of diagnosis for the period 1955 to 1984. A 60-year age limit was used to avoid bias from the reduced diagnosis of primary intracranial neoplasms in the elderly. 4 Male and female patients were grouped together in order to produce adequate numbers for analysis. The follow-up study ended on December 31, 1987. Table 1 shows the sex-and age-specific incidence rates of the 467 patients presenting with a new primary intraspinal neoplasm during the 32 years of the study. Males outnumber females before the age of 30 years but later a female preponderance is evident. The 60-to 74-year age group has the highest incidence rate. The annual age-adjusted incidence rate of new tumors per 100,000 population is 0.5 in females as opposed to 0.3 in males. Table 2 shows the incidence rates for three age groups through four 8-year periods of diagnosis. Stable trends are revealed.
Results
Incidence, Age, and Sex
Basis for the Diagnosis
Fifty-two (11%) of the 467 patients were diagnosed without histological examination: at surgery in 18 patients, at clinical examination in 17 patients, from x-ray findings in 12 patients, and from the death certificate in five cases. The remaining 415 (89%) had histologically verified tumors. Table 3 shows the major histological types in 415 patients. Meningioma is the most common tumor type (46.7%), followed by ependymoma (18.6%) and neurilemoma (10.8%). Among the 133 gliomas, ependymoma accounted for 58%, astrocytoma 19%, mixed glioma 17%, and glioblastoma only 5%. The male:female ratio was 1:6 for meningioma and 2:1 for ependymoma, with minor variations between the sexes for the other types. Table 4 gives the numbers of intracranial and intraspinal gliomas. The number of intraspinal tumors is also shown as a percentage of the total number of CNS gliomas. Altogether, 34.5% of the ependymomas were intraspinal in contrast to only 0.2% of the glioblastomas. The corresponding value for meningioma is 1 1.9% (194 of the 1632 total cases). Table 5 shows relative survival rates for patients under 60 years with meningioma or glioma for three consecutive 10-year periods. There was no change in prognosis for these groups in the different periods. Patients with intraspinal meningioma did not have reduced survival prospects, whereas the 5-year relative survival rates for patients in the glioma group were in the 60% to 70% range. Table 6 summarizes the relative survival rates for patients under 60 years with intraspinal and intracranial ependymoma, astrocytoma, and mixed glioma. The prognosis is better for patients with 
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intraspinal tumors, but the difference is statistically significant only for ependymoma. For meningioma patients the 5-year relative survival rates (_+ standard deviation) were: 99.5% _+ 2.4% for the intraspinal group and 84.1% _+ 1.5% for the intracranial group.
Discussion
Although intraspinal neoplasms are rare, they represent an important differential diagnosis in patients with back pain, gait disturbances, and radicular neurological symptoms. Data on incidence, the frequency of the different lesions, and survival prospects based on studies of stable populations are important for health care planning as well as for clinical medicine. The ageadjusted incidence rates for new tumors per 100,000 population per year were 0.5 for females and 0.3 for males. In comparison, the age-adjusted incidence rate for eye cancer was 1.0 and for male breast cancer 0.5 (The Norwegian Cancer Registry 1955 to 1986).
The incidence rates in the present population-based study are lower than those previously reported, 2'5'1~ which describe only 18, 90, and 26 patients, respectively; hence, the confidence intervals of the rates are wide. The report by Sasanelli, et al., 1~ is an updated extension of an earlier series. 8 The reporting of clinically diagnosed neoplasms to the Norwegian Cancer Registry is virtually complete, but the spinal canal is not regularly examined during an autopsy (in contrast to the cranial cavity), and no cases of asymptomatic intraspinal neoplasms were seen during the study period. Our population-based incidence rates are, therefore, minimum figures. There was no increase in the incidence rates through the study period (Table 2) , in contrast to the situation for patients over 60 years with primary intracranial neoplasms. 4 This may indicate better diagnosis of intraspinal neoplasms in the early part of the period:
Meningioma was by far the most common tumor type (46.7%) in the present series, followed by glioma (32.0%) and neurilemoma (10.8%). The corresponding figures in a large, but not population-based, series of 1322 tumors from the Mayo Clinic were 25.5%, 22.0%, and 29.0%. 11 The discrepancy between the series could be explained by fewer consultation specimens from tumor types with distinct histological features (such as meningioma and ependymoma) in the latter series.
An interesting question is whether the propensity for developing a neoplasm is similar in the brain and the spinal cord. For gliomas, the weight ratio of the spinal cord and the brain may provide a means of estimating the numbers of glial cells at hazard for neoplastic growth in the two locations. However, the distribution of the various glial cell types may vary between the regions. Approximately one-third of ependymomas develop in the spinal cord: 34.5% in our series (Table 4) and 37.4% in the series of Sloof, et al. 11 Glioblastoma, the commonest brain tumor, rarely occurs in the spinal cord. As a result, astrocytoma is more common (25 vs. six cases in our series) in the intraspinal region, a finding in accordance with the series of Sloof, et al. (81 cases of astrocytoma grades I to III vs. five of astrocytoma grade IV). The reasons for this are not known to us. There may be diagnostic and registration errors, but these are unlikely to cause this degree of bias in the case of the number of intraspinal glioblastomas. It is more likely that our findings are a clue to the understanding of glioma biology. Both etiological factors and pathogenic mechanisms should be considered as explanations of the lower incidence of intraspinal glioblastoma. Is the spinal cord better protected against, for example, irradiation (diagnostic, therapeutic, cosmic, or background), or is blood flow different from that in the brain, or is temperature better regulated within the thin spinal cord? With regard to the pathogenesis of glioblastoma, it is possible that intraspinal glial tumors are diagnosed earlier while they show a differentiated pattern. Sloof, el al., found the weight of the spinal cord to be 2.58% of the total weight of the CNS. Interestingly, intraspinal gliomas represented exactly 2.54% of all CNS gliomas in our population-based series, whereas Sloof, et al., found that figure to be 7%.
The relative survival rates for meningiomas and the total group of glial tumors were unchanged over three decades. This corresponds with the lack of specific new treatment modalities during that period. Patients with an intraspinal meningioma do not have reduced survival prospects compared with the general population. The good relative survival rates for patients with intraspinal gliomas are due to the high frequency of ependymomas (Table 4 ). In general, the prognosis was better for patients with intraspinal neoplasms than for those with intracranial tumors, but the difference was statistically significant only for meningioma and ependymoma, as previously reported for ependymoma) ~ However, the two groups could have differences with regard to age, sex, tumor size, and histological features, in addition to site. More extensive studies are therefore needed before the relative prognostic importance of tumor site can be decided. This is the largest population-based survey of primary intraspinal neoplasms published to date. The descriptive epidemiological data indicate that, in some respects, tumorigenesis in the intraspinal region differs biologically from that in the intracranial region of the CNS.
In conclusion, the annual incidence of primary intraspinal neoplasms is five per million for females and three per million for males. The time trend in incidence is stable for all age groups, which indicates an unaltered diagnostic sensitivity over the study period. Meningioma accounts for approximately one-half of the primary intraspinal tumors. Ependymoma is the most common glial tumor, whereas glioblastoma rarely develops in the spinal cord. Patients with intraspinal meningiomas have a significantly better 5-year relative survival rate than patients with intracranial meningioma. Patients with intraspinal ependymorna also have a significantly better 5-year relative survival rate than those with intracranial ependymoma.
